WuXi Biologics (Cayman) Inc.
2269
株式のランク
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
株価
$5.77
時価総額
$23.74B
変化（1日）
-8.38%
変化（1年）
25.13%
国
CN
取引 WuXi Biologics (Cayman) Inc. (2269)
カテゴリー
Healthcare
WuXi Biologics (Cayman) Inc.（2269）のP/S比率
2026 時点のP/S比率 TTM: 0
WuXi Biologics (Cayman) Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
WuXi Biologics (Cayman) Inc. の P/S 比率の履歴（2014 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2025 | 5.41 | 50.12% |
| 2024 | 3.60 | -43.29% |
| 2023 | 6.36 | -55.99% |
| 2022 | 14.44 | -55.19% |
| 2021 | 32.23 | -49.91% |
| 2020 | 64.36 | 118.36% |
| 2019 | 29.47 | 29.19% |
| 2018 | 22.81 | -6.32% |
| 2017 | 24.35 | -16.00% |
| 2016 | 28.99 | -39.77% |
| 2015 | 48.14 | -37.59% |
| 2014 | 77.13 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
